Gradient Denervation Technologies is a cutting-edge brand that offers a groundbreaking approach to treat pulmonary hypertension and heart failure. Their device-based solution aims to improve cardiovascular health and revolutionize the field of medical technology. Led by an experienced management team, including CEO Martin Grasse and CMO Dr.

Lukas Guenther, Gradient Denervation Technologies is at the forefront of innovation in healthcare. The brand also boasts a dedicated and knowledgeable Board of Directors, with members such as Lisa Wipperman Heine and Juan Pablo Mas. Their achievements speak volumes, as Gradient Denervation Technologies has been recognized and awarded prestigious grants, including the EIT Health Catapult 2020 winner in the Medtech category and the i-Lab 2020 3rd place laureate.

While their device is currently for investigational use only and not approved for commercial use, Gradient Denervation Technologies is committed to advancing medical research and improving patient outcomes. For more information about Gradient, reach out to them directly